Physician profile
Robert A Ryan
NPI 1851398630
$1,761.97
in general payments reported to CMS, 2019-2025
15 companies · $233 in 2025
The $233 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $20.34 · 2021: $268 · 2022: $394 · 2023: $535 · 2024: $95.71 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $864.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $407.40 | 2021-2025 | Tearcare System |
| Lkc Technologies, INC. | $215.77 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $200.83 | 2023-2024 | Infuse |
| Horizon Therapeutics Plc | $124.99 | 2023 | Tepezza |
| Alcon Vision LLC | $112.77 | 2023 | Acrysof Iq Panoptix Uv Iol |
| Biotissue Holdings INC. | $112.38 | 2019 | |
| Eyepoint US, INC. | $104.64 | 2023 | |
| Sun Pharmaceutical Industries INC. | $97.16 | 2022 | |
| Allergan, INC. | $91.07 | 2022 | |
| Coopervision INC. | $87.97 | 2023 | Misight Contact Lens |
| Johnson & Johnson Surgical Vision, INC. | $87.00 | 2019 | |
| Kala Pharmaceuticals, INC. | $84.25 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $19.51 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $15.40 | 2019 | |
| Travere Therapeutics, INC. | $0.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.